Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL4918810 | 0.91 | CTSK (0.47) | CTSKCTSSPTPN1SCN9AATM | |
| SCHEMBL4917131 | 0.91 | CTSS (0.55) | CTSKCTSSPTPN1SCN9AATM | |
| SCHEMBL4917142 | 0.91 | CTSS (0.55) | CTSKCTSSPTPN1SCN9AATM | |
| Tetrabuthylammonium SCHEMBL5560785 | 0.85 | CTRB1 (0.43) | CTSS | |
| SCHEMBL4923623 | 0.81 | CTSS (0.54) | CTSKCTSSPTPN1SCN9AATM | |
| SCHEMBL10077521 | 0.78 | SCN9A (0.45) | CTSKCTSSPTPN1SCN9AATM | |
| SCHEMBL4922934 | 0.77 | CTSS (0.60) | CTSKCTSSPTPN1SCN9AATM | |
| SCHEMBL7029037 | 0.77 | CTSS (0.60) | CTSKCTSSPTPN1SCN9AATM | |
| SCHEMBL4922943 | 0.77 | CTSS (0.60) | CTSKCTSSPTPN1SCN9AATM | |
| Tetrabuthylammonium SCHEMBL5560786 | 0.76 | CTRB1 (0.43) | CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275086-A1 | Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-11-06 | — | — | US | disclosed |
| EP-1702916-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275086-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | CTSK 124/4885CTSS 271/4885PTPN1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.